The number of confirmed Ebola cases in the Democratic Republic of Congo has climbed to 260 as officials updated their estimates of the outbreak’s size and international health organisations warned of the risk of further spread.
Health Minister Roger Kamba reported the revised tally on May 30 at a press conference in Bunia, the city at the epicentre of the outbreak, and said US health authorities had agreed to support Congo’s use of an experimental antibody treatment in a mid-stage trial. The research will help determine the efficacy of the medication, “which is very promising,” he said.
The outbreak, caused by the rare Bundibugyo strain of Ebola virus, has been reported across more than a dozen health zones in three Congolese provinces. Uganda has recorded nine cases, one of them fatal. Doctors Without Borders says the epidemic may be spreading faster than responders can fully assess, with hundreds of samples still awaiting testing.
“The reality today is that nobody knows the true scale and severity of this outbreak,” said Alan Gonzalez, deputy director of operations with medical group also known as Medecins Sans Frontieres, in a statement on May 30. “Never before has an Ebola outbreak recorded so many cases so soon after its declaration.”
The number of suspected cases fell to 349 on May 28 from a peak of 1,077 reported on May 26 after investigations and laboratory testing confirmed some infections and ruled out others, according to health ministry data.
Authorities have conducted more than 900 Ebola tests and expanded laboratory capacity to process 200 to 300 samples a day, Kamba said, helping investigators clarify the scale of the outbreak after weeks of uncertainty about how widely the virus had spread.
Still, new suspected cases are being reported daily, and “hundreds of samples remain untested,” Gonzalez said.
Among 84 newly confirmed cases reported late last week were five healthcare workers in Bunia, raising concern that infection control is inadequate in health facilities.
Congo received support from the US Centers for Disease Control and Prevention to pursue use of an experimental antibody treatment in a so-called phase-2 trial, Kamba said, without specifying which one. The therapy has shown promise in animal studies and early human testing, he said, with initial doses expected to arrive soon for further evaluation.
Independent experts advising the World Health Organisation last week recommended prioritising three candidate therapeutics for evaluation in clinical trials among confirmed Bundibugyo cases: the monoclonal antibodies MBP134 and Maftivimab, as well as Gilead Sciences’ antiviral remdesivir.
Even though there are no approved vaccines or treatments for the Bundibugyo strain, WHO director-general Tedros Adhanom Ghebreyesus encouraged those affected to seek early treatment.
“Ebola caused by the Bundibugyo virus can be survived with good medical care,” he told reporters Saturday in Bunia, the capital of the north-eastern province of Ituri. “Some people here in Ituri already have recovered.”
Tedros urged countries that have imposed travel restrictions to reconsider them, saying such measures can hamper outbreak response efforts and discourage transparency.
Border and airport closures are constraining an already insufficient response.
“We know from experience that these measures severely hinder outbreak response, and isolate countries that urgently need international support,” according to Gonzalez. “The number of expert medical organisations responding on the ground is still far too limited, and the level of support being provided, including our own, falls far short of what is needed.” BLOOMBERG
